A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

769

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease
IBD
Colitis
Inflammatory Bowel Disease

Interventions

DRUG: Group 2 ustekinumab 130 mg
DRUG: Group 3: ustekinumab approximately 6 mg/kg
DRUG: Group 1: Placebo

Sponsor

Janssen Research & Development, LLC